Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.53 |
| ▸ | PDE1A | P54750 | 5/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.51 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316915 | 0.86 | POLB (0.46) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316884 | 0.76 | PDE5A (0.52) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8248032 | 0.76 | PDE5A (0.55) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8240937 | 0.76 | PDE5A (0.53) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8240934 | 0.76 | MEN1 (0.57) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL13316881 | 0.75 | PDE5A (0.52) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL3607475 | 0.74 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8245297 | 0.73 | PDE5A (0.54) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8244441 | 0.72 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CKDM4E | |
| SCHEMBL8238725 | 0.72 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | PDE5A 258/4885PDE1A 3451/4885PDE1B 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.